29.83
-0.95 (-3.09%)
| Previous Close | 30.78 |
| Open | 30.50 |
| Volume | 2,178,598 |
| Avg. Volume (3M) | 1,697,519 |
| Market Cap | 4,918,996,480 |
| Price / Earnings (TTM) | 14.20 |
| Price / Earnings (Forward) | 17.76 |
| Price / Sales | 3.31 |
| Price / Book | 3.25 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Alkermes plc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.10 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.51% |
| % Held by Institutions | 107.58% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Deutsche Bank, 74.32%) | Buy |
| Median | 41.00 (37.45%) | |
| Low | 33.00 (UBS, 10.63%) | Hold |
| Average | 42.20 (41.47%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 30.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 28 May 2025 | 45.00 (50.85%) | Buy | 29.90 |
| Baird | 02 May 2025 | 41.00 (37.45%) | Buy | 31.78 |
| RBC Capital | 02 May 2025 | 40.00 (34.09%) | Hold | 31.78 |
| UBS | 28 Apr 2025 | 33.00 (10.63%) | Hold | 27.91 |
| Deutsche Bank | 27 Mar 2025 | 52.00 (74.32%) | Buy | 33.53 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NICHOLS CHRISTIAN TODD | - | 31.10 | -6,667 | -207,344 |
| WRIGHT CHRISTOPHER I | - | 31.71 | -793 | -25,146 |
| Aggregate Net Quantity | -7,460 | |||
| Aggregate Net Value ($) | -232,490 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 31.30 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NICHOLS CHRISTIAN TODD | Officer | 10 Jun 2025 | Automatic sell (-) | 3,334 | 31.06 | 103,554 |
| NICHOLS CHRISTIAN TODD | Officer | 09 Jun 2025 | Automatic sell (-) | 3,333 | 31.14 | 103,790 |
| WRIGHT CHRISTOPHER I | Director | 08 Jun 2025 | Disposed (-) | 793 | 31.71 | 25,146 |
| WRIGHT CHRISTOPHER I | Director | 08 Jun 2025 | Option execute | 3,301 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |